Fda approves recover iv randomized controlled trial with exception from informed consent (efic)

Danvers, mass.--(business wire)--abiomed (nasdaq: abmd) announces two approvals from the u.s. food and drug administration (fda) related to clinical research of impella heart pumps in acute myocardial infarction (ami) cardiogenic shock patients. the fda has approved the on-label recover iv randomized controlled trial (rct) for ami cardiogenic shock patients. recover iv is a two-arm trial that will assess whether percutaneous coronary intervention (pci), with impella support initiated prior to t
ABMD Ratings Summary
ABMD Quant Ranking